Merck MK-677

Growth hormone secretagogue Phase III trial is discontinued after mixed efficacy results from an October interim analysis. The trial, begun early in 1998, was in pediatric growth hormone deficient patients; development of MK-677 is also stalled for other populations such as the elderly, the company said